{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:05:54Z","timestamp":1790726754805,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gut dysbiosis may contribute to pain and bloating in patients with functional gastrointestinal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To determine if treatment with rifaximin would improve the symptoms of functional dyspepsia in Chinese patients in a double\u2010blinded, randomised, placebo\u2010controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Consecutive subjects with a diagnosis of functional dyspepsia as per the Rome\n                      <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                      criteria were randomised to receive rifaximin 400 mg or placebo, all taken three times daily for 2 weeks. The investigators and study subjects were blinded to the treatment allocation. Subjects were followed up for 8 weeks. The primary end point was adequate relief of global dyspeptic symptoms (\n                      <jats:styled-content style=\"fixed-case\">GDS<\/jats:styled-content>\n                      ). Secondary endpoints were relief of individual dyspeptic symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty\u2010six subjects were recruited. At week 8, there were significantly more subjects in the rifaximin than in the placebo group who experienced adequate relief of\n                      <jats:styled-content style=\"fixed-case\">GDS<\/jats:styled-content>\n                      (78% vs. 52%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02). A trend favouring rifaximin group was also noted in the preceding 4 weeks. Rifaximin was also superior to placebo in providing adequate relief of belching and post\u2010prandial fullness\/bloating (\n                      <jats:styled-content style=\"fixed-case\">PPF<\/jats:styled-content>\n                      ) in subjects at week 4. Subgroup analysis revealed that female subjects had more significant response to rifaximin treatment (adequate relief of\n                      <jats:styled-content style=\"fixed-case\">GDS<\/jats:styled-content>\n                      at week 4: 76% vs. 42%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006; week 8: 79% vs. 47%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.008), as well as improvements in their belching and\n                      <jats:styled-content style=\"fixed-case\">PPF<\/jats:styled-content>\n                      at week 4. The incidences of adverse effects were similar in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment with 2 weeks of rifaximin led to adequate relief of global dyspeptic symptoms, belching and post\u2010prandial fullness\/bloating in subjects with functional dyspepsia. The difference was more marked in females. (clinicaltrials.org\n                      <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n                      01643083).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.13945","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T05:27:44Z","timestamp":1485149264000},"page":"767-776","source":"Crossref","is-referenced-by-count":126,"title":["Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5721-8807","authenticated-orcid":false,"given":"V. P. Y.","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-8808","authenticated-orcid":false,"given":"K. S. H.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Y. F.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. F. N.","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F.","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Hong Kong Queen Mary Hospital Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2012.18.2.150"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01939.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307843"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm14045"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05984.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2005.00627.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i42.6127"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004409"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00458.x"},{"key":"e_1_2_7_11_1","article-title":"Dyspepsia and the microbiome: time to focus on the small intestine","author":"Zhong L","year":"2016","journal-title":"Gut"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13434"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12419"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303857"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3285-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.026"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365520903551332"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03006.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/cs0950165","article-title":"Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study","volume":"95","author":"Lu CL","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000122"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1540\/jsmr.50.78"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06370.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.01.001"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2015.02.001"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04566.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13945","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T08:14:22Z","timestamp":1695456862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/apt.13945"],"URL":"https:\/\/doi.org\/10.1111\/apt.13945","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727233700.793527847","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,23]]}}}